ZPBP2: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of ZPBP2. The page also collects GeneMedi's different modalities and formats products for ZPBP2 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the ZPBP2 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Secreted Protein/Potential Cytokines.

Predicted to be involved in acrosome assembly and binding activity of sperm to zona pellucida. Predicted to act upstream of or within membrane lipid metabolic process and regulation of gene expression. Located in nucleus. [provided by Alliance of Genome Resources, Apr 2022]

Target IDGM-SE1389
Target NameZPBP2
Gene ID124626,69376,363676,698217,480531,101101601,514334,100068017
Gene Symbol and Synonyms1700017D11Rik,2610022C02Rik,ZPBP2,ZPBPL
Uniprot AccessionQ6X784,Q6X782
Uniprot Entry NameZPBP2_HUMAN,ZPBP2_RAT
Protein Sub-locationSecreted Protein/Potential Cytokines
Category
DiseaseN/A
Gene EnsemblENSG00000186075
Target ClassificationN/A


Pre-made anti-ZPBP2 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-ZPBP2 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-ZPBP2 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Antibody NameSpeciesFormatClassified by tagDetail
Anti-ZPBP2 monoclonal antibodyHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquinemabFACS/Biofunctional AntibodyDetail



Recombinant multi-species ZPBP2/ ZPBPL protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ZPBP2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Products NameSpeciesExpression PlatformDetail
ZPBP2 proteinHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquineMammalian cellDetail



Pre-made ZPBP2 viral vector in GM Promise-ORFTM

Cat No.Products nameNM IDSpeciesTypeDetail
pGMLP003346human ZPBP2 Lentivirus plasmidNM_198844HumanLentivirus plasmidDetail
vGMLP003346human ZPBP2 Lentivirus particleNM_198844HumanLentivirus particleDetail
pGMLPm001284mouse Zpbp2 Lentivirus plasmidNM_199419.3MouseLentivirus plasmidDetail
vGMLPm001284mouse Zpbp2 Lentivirus particleNM_199419.3MouseLentivirus particleDetail

About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI

If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.






GENEMEDI
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
<